A multicentre open label non-comparative phase-IV study to evaluate safety, tolerability and anti-PRP-T antibody Persistence of BEâ??s Combined Liquid Pentavalent DTwP-rHepB-HIB vaccine in 6-8 week old infants as per routine EPI Immunization Schedule - None

Trial Profile

A multicentre open label non-comparative phase-IV study to evaluate safety, tolerability and anti-PRP-T antibody Persistence of BEâ??s Combined Liquid Pentavalent DTwP-rHepB-HIB vaccine in 6-8 week old infants as per routine EPI Immunization Schedule - None

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Hib-DTP-hepatitis B vaccine (Primary)
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Biological E Limited
  • Most Recent Events

    • 03 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 07 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top